ACLX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Arcellx Inc (ACLX) is not a good buy for a beginner, long-term investor at this time. The stock is in the process of being acquired by Gilead Sciences for $115 per share, which limits its upside potential. Additionally, insider selling has increased significantly, and analysts have downgraded the stock to Neutral or Hold, citing the acquisition. While there are no significant positive catalysts or trading signals, the financial performance and technical indicators do not suggest a compelling entry point.
The MACD is negative and expanding (-1.636), indicating bearish momentum. RSI is neutral at 74.643, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its pivot point (114.586) with limited movement, suggesting a lack of strong directional momentum.
NULL. The acquisition by Gilead provides a clear price ceiling at $115 per share, leaving minimal room for upside.
Insider selling has increased by 642.87% over the last month. Analysts have downgraded the stock to Neutral or Hold due to the acquisition. Legal investigations into the acquisition could create uncertainty.
In Q4 2025, revenue dropped significantly by -89.17% YoY to $1.65 million. However, net income improved to -$58.11 million (+23.43% YoY), and EPS increased to -1 (+14.94% YoY). Gross margin remained stable at 100%. Overall, financials are weak with no clear growth trends.
Analysts have downgraded the stock to Neutral or Hold due to Gilead's acquisition offer of $115 per share. The consensus is that the acquisition price is fair, and no competing offers are expected.
